On July 4, 2022, Algernon Pharmaceuticals Inc. (“Algernon”) announced the closing of its previously announced marketed public offering for gross proceeds of C$1,159,188.75 with Research Capital Corporation as the sole agent and sole bookrunner. Algernon issued an aggregate of 309,117 units at a price of C$3.75 per unit. The proceeds are anticipated to be used to fund research and development programs, general and administrative expenses and for working capital purposes.
Fasken advised Research Capital Corporation, with a team led by John Sabetti (Corporate Finance and Securities), and which included David Pak, Andreea Andrei and Josh Hersh (Corporate Finance and Securities), Mitchell Thaw (Tax), Armand Benitah and Nathan Haldane (Intellectual Property), and Mark Vanderveken (Healthcare Regulatory).
Jurisdiction
- Ontario
